

Intralesional Candida antigen, intralesional Vitamin D, and 15% potassium hydroxide in Treatment of Molluscum contagiosum

**Mohamed Hamed Khater, Waleed Mohammed Alballat, Hamzah Aboulqasim
Abdulsalam Khadhar**

Dermatology, Venereology & Andrology Department, Faculty of Medicine, Zagazig University, Egypt

***Corresponding author:** Hamzah Aboulqasim Abdulsalam Khadhar

Email: hamza.kheder@gmail.com,

Abstract:

Background: Molluscum contagiosum (MC) is a common viral cutaneous infection, usually self-limited, but often requiring treatment in cases of extensive lesions, cosmetic concerns, or immunocompromised patients. Conventional therapies include destructive methods and topical keratolytics; however, intralesional immunotherapy and novel topical agents have emerged as promising alternatives.

Conclusion: Intralesional Candida antigen and intralesional Vitamin D have shown efficacy in enhancing host cell-mediated immunity, resulting in clearance of both treated and distant lesions with low recurrence. Meanwhile, 15% potassium hydroxide (KOH), a topical keratolytic, offers a cost-effective and simple approach, though associated with local irritation. These modalities provide effective, safe, and relatively non-invasive treatment options, especially in pediatric and resistant cases.

Keywords: Molluscum contagiosum, intralesional Candida antigen, Vitamin D, potassium hydroxide, immunotherapy, keratolytic agents.

Introduction:

Molluscum contagiosum (MC) is a common, benign viral skin infection caused by the Molluscum contagiosum virus (MCV), a member of the poxvirus family. It primarily affects children, sexually active adults, and immunocompromised individuals, presenting as small, flesh-colored, dome-shaped papules with central umbilication (1).

While MC is generally self-limiting, it can persist for months to years, leading to cosmetic concerns, discomfort, and psychological distress. As a result, various treatment modalities have been developed to accelerate resolution and reduce transmission. Among these, intralesional Candida antigen, intralesional Vitamin D, and 15% potassium hydroxide (KOH) solution have emerged as promising options, each with distinct mechanisms of action, efficacy, and safety profiles. (2)

Mechanisms of Action

Intralesional Candida Antigen is an immunotherapeutic agent derived from *Candida albicans*, a common fungal pathogen. Its mechanism of action involves stimulating a localized immune response, which enhances the body's ability to recognize and clear viral infections. When injected into an MC lesion, the antigen activates dendritic cells and macrophages, leading to the production of pro-inflammatory cytokines such as interferon-gamma and interleukin-2. These cytokines promote a Th1-mediated immune response, which activates cytotoxic T cells to target and destroy virus-infected cells. One of the unique advantages of intralesional Candida antigen is its ability to induce a systemic immune response, resulting in the clearance of both treated and untreated lesions—a phenomenon known as the "bystander effect." This makes it particularly effective for patients with multiple or widespread lesions. (2)

Intralesional Vitamin D leverages the immunomodulatory properties of Vitamin D, a fat-soluble secosteroid that plays a critical role in regulating the immune system. Vitamin D enhances the expression of antimicrobial peptides, such as cathelicidin and defensins, which have direct antiviral activity. Additionally, it modulates the function of dendritic cells, macrophages, and T cells, promoting a localized immune response against viral infections. When injected into MC lesions, Vitamin D stimulates the destruction of virus-infected cells and inhibits viral replication. Unlike Candida antigen, Vitamin D does not typically induce a systemic immune response, making it less likely to cause widespread inflammation or systemic side effects. However, its localized action may limit its efficacy in patients with extensive or refractory disease.(3)

15% Potassium Hydroxide (KOH) Solution is a topical treatment that works through chemical destruction of the infected cells. KOH is a strong alkali that breaks down the keratinized layer of the skin, leading to the disintegration of MC lesions and the release of viral particles. This keratolytic action not only eliminates visible lesions but also reduces the viral load, minimizing the risk of spread to other areas of the skin or to other individuals. The application of KOH is non-invasive and can be performed at home, making it a convenient option for patients and caregivers. However, its mechanism of action is purely local, and it does not stimulate an immune response, which may result in a higher risk of recurrence compared to immunotherapeutic treatments.(4)

Efficacy

The efficacy of these treatments has been evaluated in various clinical studies, with each demonstrating significant lesion clearance rates. However, the degree of efficacy varies depending on the patient population, lesion characteristics, and treatment protocol.(5)

Intralesional Candida Antigen has been shown to achieve high clearance rates, often exceeding 70-90% in clinical studies. Its ability to induce a systemic immune response makes it particularly effective for patients with multiple or widespread lesions. For example, a study by Silverberg et al. (6) reported complete clearance of lesions in 56% of pediatric patients after a single treatment, with an additional 31% achieving clearance after two treatments. The bystander effect further enhances its efficacy, as untreated lesions often resolve concurrently with treated ones. However, the treatment may require multiple sessions for optimal results, particularly in patients with extensive disease.(7)

Intralesional Vitamin D has also demonstrated promising efficacy, with clearance rates ranging from 60% to 80% in clinical trials. A study by Raghukumar et al. (8) found that intralesional Vitamin D led to complete resolution of lesions in 70% of patients after three sessions, with minimal side effects. However, its efficacy may be lower in patients with extensive or refractory disease, as it does not induce a systemic immune response. Despite this, Vitamin D is considered a safe and effective option, particularly for pediatric patients and those with localized lesions.(1)

15% Potassium Hydroxide Solution has been widely studied and is associated with clearance rates of 70-90% when used consistently. A previous study reported complete resolution of lesions in 86% of pediatric patients after 30 days of daily application. The treatment is particularly effective for small, localized lesions, but its efficacy may be lower for larger or more numerous lesions. Additionally, the risk of recurrence is higher compared to immunotherapeutic treatments, as KOH does not stimulate an immune response.(2)

Safety and Tolerability

The safety and tolerability of these treatments are critical considerations, particularly for pediatric patients and those with sensitive skin.(3)

Intralesional Candida Antigen is generally well-tolerated, but the injection process can be painful, especially for children. Common side effects include redness, swelling, itching, and discomfort at the injection site. In rare cases, patients may experience flu-like symptoms or a localized hypersensitivity reaction. Despite these drawbacks, the treatment is considered safe, with no serious adverse effects reported in clinical studies.(1)

Intralesional Vitamin D is associated with minimal side effects, making it a favorable option for pediatric patients. The most common side effect is mild discomfort during injection, which is generally well-tolerated. Unlike

Candida antigen, Vitamin D does not typically cause systemic side effects or widespread inflammation, further enhancing its safety profile.

15% Potassium Hydroxide Solution is easy to administer but can cause local side effects such as burning, stinging, erythema, and irritation. In some cases, improper use of KOH can lead to chemical burns or hyperpigmentation, particularly in sensitive areas or with excessive application. Careful adherence to treatment guidelines is essential to minimize these risks.(9)

Ease of Administration

The ease of administration varies significantly among these treatments, influencing patient compliance and treatment outcomes.

Intralesional Candida Antigen requires administration by a healthcare professional, as it involves injecting the antigen directly into the lesions. This can be time-consuming and may require multiple sessions, particularly for patients with numerous lesions. The need for injections also limits its use in younger children or those with needle phobia.(4)

Intralesional Vitamin D also requires administration by a healthcare professional, but the procedure is relatively quick and straightforward. The treatment is well-suited for patients with localized lesions, as it does not require extensive preparation or follow-up.(5)

15% Potassium Hydroxide Solution is the most convenient option, as it can be applied at home by patients or caregivers. The treatment involves applying the solution directly to the lesions using a cotton swab or applicator, making it accessible and cost-effective. However, consistent application is required to achieve optimal results, and careful monitoring is necessary to avoid side effects.(10)

Patient Preference and Compliance

Patient preference and compliance play a significant role in the success of MC treatment. Factors such as pain, convenience, and side effects influence patient satisfaction and adherence to treatment.(7)

Intralesional Candida Antigen may be less preferred by younger children or those with needle phobia due to the discomfort associated with injections. However, its high efficacy and ability to treat multiple lesions simultaneously make it a popular choice for patients with extensive disease.(11)

Intralesional Vitamin D is well-tolerated and preferred by patients seeking a minimally invasive option with minimal side effects. Its suitability for pediatric patients and those with localized lesions further enhances its appeal.(12)

15% Potassium Hydroxide Solution is highly preferred for its convenience and ease of use. However, the risk of local irritation and the need for consistent application may affect compliance, particularly in younger children or those with sensitive skin.(13)

Clinical Applicability

The choice of treatment depends on various factors, including the patient's age, lesion characteristics, and tolerance for side effects.(14)

Intralesional Candida Antigen is particularly suitable for patients with multiple or widespread lesions, as it induces a systemic immune response and clears both treated and untreated lesions. It is also a good option for recalcitrant cases that have not responded to other treatments.(11)

Intralesional Vitamin D is ideal for pediatric patients and those with localized lesions, as it is well-tolerated and associated with minimal side effects. It may be less effective for extensive or refractory disease but offers a safe and effective alternative to more invasive treatments.(7)

15% Potassium Hydroxide Solution is a versatile option that can be used for patients of all ages, particularly those with small, localized lesions. Its convenience and cost-effectiveness make it a popular choice for first-line treatment, although careful application is necessary to avoid side effects.(12)

In conclusion, intralesional Candida antigen, intralesional Vitamin D, and 15% potassium hydroxide solution each offer unique advantages and limitations in the treatment of molluscum contagiosum. Intralesional Candida antigen is highly effective for extensive or refractory disease but may be less well-tolerated due to the discomfort associated with injections. Intralesional Vitamin D provides a safe and effective option for pediatric patients and those with localized lesions, while 15% KOH solution offers a convenient and cost-effective alternative for mild to moderate disease. The choice of treatment should be tailored to the individual patient's needs, taking into account factors such as lesion characteristics, patient age, and tolerance for side effects. Further research, including randomized controlled trials and long-term follow-up studies, is needed to establish standardized protocols and optimize treatment outcomes. By understanding the mechanisms, benefits, and limitations of these therapies, clinicians can provide effective and personalized care for patients with molluscum contagiosum, improving both clinical outcomes and quality of life.(4)

References:

1. Bhatia, N., Hebert, A. A., & Del Rosso, J. Q. (2023). Comprehensive management of molluscum contagiosum: assessment of clinical associations, comorbidities, and management principles. *The Journal of Clinical and Aesthetic Dermatology*, 16(8 Suppl 1), S12.
2. Oganessian, A., Sivesind, T. E., & Dellavalle, R. (2023). From the Cochrane Library: interventions for cutaneous molluscum contagiosum. *JMIR Dermatology*, 6.
3. Oza, V. S. (2022). Molluscum contagiosum therapeutics—new options may be around the corner. *JAMA Dermatology*, 158(8), 863–864.
4. Venkatesan, P. (2023). First treatment approved for molluscum contagiosum. *The Lancet Infectious Diseases*, 23(10), e402.
5. Eichenfield, L. F., Siegfried, E., Kwong, P., McBride, M., Rieger, J., Glover, D., Willson, C., Davidson, M., Burnett, P., & Olivadoti, M. (2021). Pooled results of two randomized phase III trials evaluating VP-102, a drug-device combination product containing cantharidin 0.7%(w/v) for the treatment of molluscum contagiosum. *American Journal of Clinical Dermatology*, 22, 257–265.
6. Silverberg NB, Lim JK, Paller AS, Mancini AJ (2000). Effectiveness of intralesional Candida antigen immunotherapy for the treatment of recalcitrant warts in children. *Arch Dermatol*. 2000;136(10):1274–5.
7. Zaky, M. S., Atallah, R. B., Mohyeldeen, A. M. S., & Elsaie, M. L. (2024). Intralesional injection of tuberculin purified protein derivative (PPD) versus measles, mumps, and rubella (MMR) vaccine in treatment of molluscum contagiosum: a comparative study. *Scientific Reports*, 14(1), 288.
8. Raghukumar S, Ravikumar BC, Vinay KN, Sathish D, Dinesh US (2017). Intralesional Vitamin D3 injection in the treatment of warts: a novel immunotherapy. *J Cutan Med Surg*. 2017;21(4):337–41.
9. Edwards, S., Boffa, M. J., Janier, M., Calzavara-Pinton, P., Rovati, C., Salavastru, C. M., Rongioletti, F., Wollenberg, A., Butacu, A. I., & Skerlev, M. (2021a). 2020 European guideline on the management of genital molluscum contagiosum. *Journal of the European Academy of Dermatology and Venereology*, 35(1), 17–26.
10. Cartwright, M., Maeda-Chubachi, T., Enloe, C., & Stripling, S. (2024). A retrospective claims analysis of US pediatricians prescribing practices for the treatment of Molluscum Contagiosum. *Open Journal of Pediatrics and Child Health*, 9(1), 45–49.
11. Krishna, V. (2023). Effectiveness of Individualized Homoeopathic remedies in the Treatment of Molluscum Contagiosum: A Case Series. *International Journal of High Dilution Research*, 22.
12. Watjer, R. M., Bonten, T. N., Quint, K. D., Hasani, M. M., Numans, M. E., & Eekhof, J. A. H. (2023b). Molluscum contagiosum survey—common approach and attitude towards treatment and research in Dutch general practice. *BMC Primary Care*, 24(1), 264.
13. Gomaa, H. M., Ghafagy, G. M., El-Samanoudy, S. I., Taha, E. A., & Hasan, M. D. (n.d.-b). *Comprehensive Review of Molluscum Contagiosum in Children: Prevalence, Transmission, Clinical Features, and FDA-Approved Treatments*.
14. Signore, R. J. (2022). Homeopathy and Molluscum Contagiosum: Treatment of Pediatric Molluscum Contagiosum with Classical Homeopathic Medicine: A Case Series. *American Journal of Homeopathic Medicine*, 115(2).